L
Lisa T. Dooley
Researcher at University of Medicine and Dentistry of New Jersey
Publications - 21
Citations - 8052
Lisa T. Dooley is an academic researcher from University of Medicine and Dentistry of New Jersey. The author has contributed to research in topics: Infliximab & Psoriasis. The author has an hindex of 18, co-authored 21 publications receiving 7670 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi,Alexa B. Kimball,Kim A. Papp,Newman Yeilding,Cynthia Guzzo,Y. Wang,Shu Li,Lisa T. Dooley,Kenneth B. Gordon +8 more
TL;DR: Ustekinumab seems to be efficacious for the treatment of moderate-to-severe psoriasis; dosing every 12 weeks maintains efficacy for at least a year in most patients.
Journal ArticleDOI
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis : a phase III, multicentre, double-blind trial
Kristian Reich,Frank O. Nestle,Kim A. Papp,Jean-Paul Ortonne,Robert Evans,Cynthia Guzzo,Shu Li,Lisa T. Dooley,Christopher E.M. Griffiths +8 more
TL;DR: Infliximab is effective in both an induction and maintenance regimen for the treatment of moderate-to-severe psoriasis, with a high percentage of patients achieving sustained PASI 75 and PASi 90 improvement through 1 year.
Journal ArticleDOI
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
TL;DR: Patients receiving the anti-TNF-alpha agent infliximab as monotherapy experienced a high degree of clinical benefit and rapid time to response in the treatment of moderate to severe plaque psoriasis compared with patients who received placebo.
Journal ArticleDOI
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E.M. Griffiths,Bruce Strober,Peter C.M. van de Kerkhof,Vincent T. Ho,Roseanne Fidelus-Gort,Newman Yeilding,Cynthia Guzzo,Yichuan Xia,B. Zhou,Shu Li,Lisa T. Dooley,Neil H. Goldstein,Alan Menter +12 more
TL;DR: The efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high-dose etanercept over a 12-week period in patients with psoriasis.
Journal ArticleDOI
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
Gerald G. Krueger,Richard G. Langley,Craig L. Leonardi,Newman Yeilding,Cynthia Guzzo,Y. Wang,Lisa T. Dooley,Mark Lebwohl +7 more
TL;DR: This double-blind, placebo-controlled trial demonstrates the therapeutic efficacy of an interleukin-12/23 monoclonal antibody in psoriasis and provides further evidence of a role of the interleUKin- 12/23 p40 cytokines in the pathophysiology of Psoriasis.